Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price3.89 USD
Fair value6.25Our model only; only one analyst covers it, too few to cross-check it.
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-02Read Markdown4.70-17.2% to today ✓Markup gives way to Markdown after a 17% rise in 8 weeks
2026-08-07Read Markup4.03-3.5% to today Distribution gives way to Markup
2026-07-02Read Distribution3.87+0.5% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Oramed Pharmaceuticals Inc holds its Markdown at $3.89. The statistical read favours the sellers, held for 21 days.
As held on the ledger · 2026-11-05
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 21 days
Price at the screen
$3.89
Valuation
1.81 trailing · -50.38 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.20
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.36%
Below 33%
Interest-bearing debt is just 0.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
5.95%
Below 33%
Cash held in interest-bearing accounts and securities is 6.0% of assets, under the one-third limit.
Pass
Receivables
21.91%
Below 49%
Money owed to the company is 21.9% of assets, under the 49% limit.
Pass
Revenue purity
100.00%
Below 5%
100.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Oramed Pharmaceuticals clears the business-activity screen, and its debt is near-nil. Where it falls short is income purity: around 100% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ORMP's ethical verdict changes
Today ORMP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; only one analyst covers it, too few to cross-check it.
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 34% discount to our $6.25 fair value, none competitive moat.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 37.8% discount to the base estimate.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Where our models see it going: fair-value estimate $6.25, range not available, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
Trading at -50.4x forward earnings, with a none competitive moat and minimal debt. That is a 34% discount to our $6.25 fair value: the market is pricing it cautiously while the fundamentals argue otherwise.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ORMP trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-02Markdown$4.11-0.7%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it strong buy, with a mean price target of $6. Insiders have been net sellers over the past quarter.
2026-10-21Markdown$4.14-11.9%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it strong buy, with a mean price target of $6. Insiders have been net sellers over the past quarter.
2026-10-02Markdown · changed$4.70+16.6%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 16.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 27% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-09-08Markup$4.03+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 27% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-08-07Markup · changed$4.03+4.1%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 27% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-07-18Distribution$3.87+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 27% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (1 analysts) rates it strong buy, with a mean price target of $6.
2026-07-03Distribution$3.87+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$3.87Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.